U.S. markets close in 5 hours 18 minutes
  • S&P 500

    4,634.82
    -20.45 (-0.44%)
     
  • Dow 30

    34,945.14
    -190.80 (-0.54%)
     
  • Nasdaq

    15,747.46
    -35.37 (-0.22%)
     
  • Russell 2000

    2,217.18
    -24.79 (-1.11%)
     
  • Crude Oil

    67.93
    -2.02 (-2.89%)
     
  • Gold

    1,803.50
    +18.30 (+1.03%)
     
  • Silver

    23.23
    +0.38 (+1.65%)
     
  • EUR/USD

    1.1337
    +0.0044 (+0.39%)
     
  • 10-Yr Bond

    1.4120
    -0.1180 (-7.71%)
     
  • GBP/USD

    1.3324
    +0.0013 (+0.10%)
     
  • USD/JPY

    113.2170
    -0.3910 (-0.34%)
     
  • BTC-USD

    58,691.53
    +1,714.11 (+3.01%)
     
  • CMC Crypto 200

    1,492.41
    +49.63 (+3.44%)
     
  • FTSE 100

    7,087.71
    -22.24 (-0.31%)
     
  • Nikkei 225

    27,821.76
    -462.16 (-1.63%)
     

What Type Of Shareholders Own The Most Number of Homology Medicines, Inc. (NASDAQ:FIXX) Shares?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

If you want to know who really controls Homology Medicines, Inc. (NASDAQ:FIXX), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that used to be publicly owned tend to have lower insider ownership.

Homology Medicines is not a large company by global standards. It has a market capitalization of US$604m, which means it wouldn't have the attention of many institutional investors. In the chart below, we can see that institutional investors have bought into the company. Let's take a closer look to see what the different types of shareholders can tell us about Homology Medicines.

Check out our latest analysis for Homology Medicines

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Homology Medicines?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Homology Medicines. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Homology Medicines' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Homology Medicines is not owned by hedge funds. Our data shows that Arch Venture Partners, L.P. is the largest shareholder with 11% of shares outstanding. In comparison, the second and third largest shareholders hold about 9.9% and 9.0% of the stock.

We did some more digging and found that 7 of the top shareholders account for roughly 53% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Homology Medicines

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own less than 1% of Homology Medicines, Inc.. It has a market capitalization of just US$604m, and the board has only US$5.3m worth of shares in their own names. Many tend to prefer to see a board with bigger shareholdings. A good next step might be to take a look at this free summary of insider buying and selling.

General Public Ownership

With a 13% ownership, the general public have some degree of sway over Homology Medicines. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With a stake of 21%, private equity firms could influence the Homology Medicines board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Public Company Ownership

It appears to us that public companies own 14% of Homology Medicines. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Homology Medicines better, we need to consider many other factors. For instance, we've identified 4 warning signs for Homology Medicines that you should be aware of.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.